Lyra Therapeutics Inc
lyratherapeutics.comLyra Therapeutics (NASDAQ: LYRA) is a clinical-stage biopharmaceutical company that develops drug candidates for ear, nose, and throat conditions. The company has generated no product revenue and funds operations through equity offerings, including common stock and warrant issuances under an at-the-market program. Its two lead candidates are LYR-210 and LYR-220. Following the failure of the ENLIGHTEN 1 clinical trial to meet its primary endpoint in May 2024, Lyra's Board approved a workforce reduction affecting 87 employees, suspending active clinical development. Restructuring charges totaled $10.9 million for FY2024 and $1.5 million for FY2025. As of the 10-K filed March 31, 2026, the company's cash and cash equivalents were projected to fund operations into the third quarter of 2026. Lyra previously licensed LYR-210 development and commercialization rights to LianBio for certain territories. Maria Palasis, Ph.D. serves as Principal Executive Officer and Jason Cavalier as Principal Financial Officer.
Products & Services
LYR-210 and LYR-220 are the company's two disclosed drug candidates, with clinical development suspended as of the 10-K filed March 31, 2026. LYR-210 was the subject of the ENLIGHTEN 1 Phase 3 clinical trial, which failed to meet its primary endpoint. LYR-210 was also licensed to LianBio for development and commercialization in certain territories, with Lyra responsible for manufacturing clinical supply.
Revenue Model
Lyra has generated no product revenue as of FY2025. Historical revenue came from a licensing and supply arrangement with LianBio covering LYR-210 development and commercialization rights, recognized under ASC 606. The company funds operations through equity capital raises, including common stock, pre-funded warrants, and ATM offerings. Interest income on cash equivalents and short-term investments totaled $1.1 million for FY2025, down from $3.0 million in FY2024.
Customers & Markets
LianBio is the sole identified customer under ASC 606 accounting, through a licensing and clinical supply arrangement for LYR-210. No commercial product customers exist as of FY2025. End markets targeted by the pipeline are ear, nose, and throat (ENT) conditions, based on the company's disclosed development focus.
Financial Snapshot
Loading...
